Endo Int'l (ENDP) Tops Q3 EPS by 24c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- SanDisk shares fall on election and chip sector pressure
- Seagate Technology shares drop amid sector selloff
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Endo Reports Third-Quarter 2017 Financial Results
November 9, 2017 4:01 PM ESTDUBLIN, Nov. 9, 2017 /PRNewswire/ --
Third-quarter 2017 revenues of $787 million and reported $0.45 diluted (GAAP) loss per share from continuing operations Third-quarter 2017 adjusted diluted earnings per share (EPS) from continuing operations of $0.91 Third-quarter 2017 Sterile Injectables revenues increased 28 percent to $175 million Third-quarter 2017 Branded Specialty Products revenues increased 11 percent to $114 million Third-quarter 2017 reported (GAAP) consolidated net loss of $97 million Third-quarter 2017 adjusted EBITDA of $375 million Company reaffirms full year 2017 revenues, adjusted diluted EPS and adjusted EBITDA financial guidance provided in August 2017Endo... More



